Last updated: August 23, 2026
Cyklokapron is the branded injectable form of tranexamic acid, an antifibrinolytic used to reduce bleeding. Its commercial position is mature and largely genericized. Pfizer retains the Cyklokapron brand in certain markets, but the product does not generate separately reported revenue in Pfizer’s public financial statements. Market value now comes primarily from broad institutional use, generic injectable competition, and demand in surgery, trauma, obstetrics, dentistry, and bleeding disorders.
What is Cyklokapron and how does it generate revenue?
Cyklokapron contains tranexamic acid, a synthetic lysine analog that inhibits plasminogen activation and reduces fibrin degradation. The U.S. product is an intravenous injection used for short-term treatment of cyclic heavy menstrual bleeding under the Cyklokapron label and for other bleeding indications under clinical protocols and institutional practice. The drug is also sold globally under the Cyklokapron name and as generic tranexamic acid injection.
The commercial model is hospital-driven:
- Hospitals purchase injectable tranexamic acid through wholesalers, group purchasing organizations and government channels.
- Generic suppliers compete mainly on price, supply reliability, sterile manufacturing capacity and contract access.
- Pfizer’s branded product competes against lower-priced generic ampules and vials.
- Revenue is distributed across multiple suppliers rather than concentrated in a single innovator product.
Tranexamic acid has broad clinical utility and low unit-cost exposure. That combination supports high-volume demand but limits pricing power.
What is the FDA regulatory status of Cyklokapron?
Cyklokapron injection was approved by the FDA under NDA 019281. The product is indicated for the reduction or prevention of bleeding in patients with hemophilia undergoing tooth extraction and for short-term use in patients with cyclic heavy menstrual bleeding, according to the product labeling.[1]
FDA status and dosage forms
| Product |
Active ingredient |
Route |
Regulatory position |
| Cyklokapron injection |
Tranexamic acid |
Intravenous |
Approved brand product |
| Generic tranexamic acid injection |
Tranexamic acid |
Intravenous |
Multiple ANDA-based competitors |
| Lysteda |
Tranexamic acid |
Oral tablet |
Separate branded product and NDA |
| Generic tranexamic acid tablets |
Tranexamic acid |
Oral |
Multiple generic competitors |
The injectable and oral products should not be treated as a single commercial franchise. Cyklokapron is primarily an institutional injectable product, while Lysteda and generic tranexamic acid tablets address outpatient heavy menstrual bleeding and other oral-use markets.
When did Cyklokapron lose exclusivity?
Cyklokapron is an old small-molecule product with no meaningful remaining U.S. market exclusivity. Its commercial protection is based on brand recognition, hospital contracts and supply reliability rather than patent exclusivity.
Exclusivity timeline
| Event |
Commercial effect |
| Original approval |
Established tranexamic acid as a regulated pharmaceutical product |
| Patent and regulatory exclusivity periods |
Expired before the current market period |
| Generic injectable approvals |
Shifted purchasing power toward price and supply |
| Current market |
Mature multisupplier hospital market |
The FDA does not provide Cyklokapron with modern reference-product exclusivity comparable to a recently approved new molecular entity. There is no current five-year NCE exclusivity period, orphan exclusivity period or pediatric exclusivity period associated with the mature Cyklokapron franchise in the United States.
What patents protect Cyklokapron?
No commercially significant, unexpired U.S. patent estate is generally associated with the mature Cyklokapron injectable product. Tranexamic acid was developed decades ago, and core composition-of-matter protection has expired.
Patent strength
| Patent category |
Current relevance |
| Tranexamic acid composition of matter |
Expired |
| Basic injectable formulation |
No meaningful exclusivity identified |
| Manufacturing process |
Potentially relevant as know-how, but not a broad product barrier |
| Method of use |
Some jurisdiction-specific claims may exist for particular indications, but they do not generally protect hospital use of the mature injectable product |
| Device or delivery technology |
Limited relevance to standard intravenous vials and ampules |
The principal remaining barriers are regulatory compliance, sterile manufacturing validation, quality systems, procurement qualification and supply continuity. These are operational barriers, not high-strength patent barriers.
What is the Orange Book status of Cyklokapron?
Cyklokapron’s U.S. market position is not supported by a meaningful current Orange Book patent shield. The product is listed as an approved prescription drug, but the commercial significance of any Orange Book listing is limited because generic tranexamic acid injection is available and the core product protection has expired.[2]
An Orange Book listing does not by itself indicate current exclusivity. For Cyklokapron, the relevant commercial question is whether an ANDA applicant must address an unexpired listed patent. The mature product’s generic competition indicates that patent-based blocking rights are not preventing market entry.
Which companies compete with Cyklokapron?
Competition comes from generic tranexamic acid manufacturers rather than a single direct branded rival. Suppliers vary by country and by hospital procurement contract. U.S. generic competition has included established injectable manufacturers such as Hikma Pharmaceuticals, Fresenius Kabi and other FDA-approved ANDA holders, subject to product availability and current listing status.[3]
Competitive products
| Product or competitor class |
Competitive role |
| Generic tranexamic acid injection |
Primary substitute for Cyklokapron |
| Aminocaproic acid injection |
Pharmacologic alternative in selected bleeding settings |
| Aprotinin |
Limited and indication-specific alternative; regulatory status varies |
| Blood products and surgical hemostatic agents |
Adjunct or replacement tools in procedural settings |
| Oral tranexamic acid |
Alternative for outpatient indications, not a direct substitute for intravenous use |
Tranexamic acid’s strongest competitive advantage is clinical familiarity across multiple specialties. Its main weakness is commoditization. Hospitals can often switch suppliers without changing treatment protocols, provided concentration, presentation, quality and availability are acceptable.
How large is the addressable market for tranexamic acid?
The market is broad but fragmented. Demand is linked to procedure volume rather than to one chronic disease population.
Major demand centers include:
- Orthopedic and cardiac surgery.
- Obstetric hemorrhage and postpartum hemorrhage.
- Trauma and emergency medicine.
- Dental extraction in patients with hemophilia.
- Gynecologic bleeding.
- Liver transplantation and other high-blood-loss procedures.
- Menstrual bleeding and outpatient gynecologic care.
Large clinical trials have supported use in trauma and postpartum hemorrhage. The CRASH-2 trial found that early tranexamic acid reduced mortality from bleeding in trauma patients, while the WOMAN trial evaluated tranexamic acid in postpartum hemorrhage.[4,5] These studies expanded the drug’s relevance beyond its original niche.
Global health adoption also supports demand. The World Health Organization includes tranexamic acid on its Model List of Essential Medicines, which strengthens public-sector procurement and use in resource-constrained health systems.[6]
What is the financial trajectory for Cyklokapron?
Cyklokapron does not have a separately disclosed revenue line in Pfizer’s annual reporting. Pfizer reports revenue by broader business segments and product groups, and the company’s public filings do not provide a standalone Cyklokapron sales history.[7]
The financial trajectory is therefore best described through market structure:
- Early lifecycle growth was driven by clinical adoption of tranexamic acid.
- Generic entry reduced branded pricing and shifted demand toward low-cost suppliers.
- Mature use expanded volume in surgery, trauma and obstetrics.
- Current value is likely stable to modestly growing in units, while branded revenue remains constrained by generic substitution.
- Supply interruptions can temporarily improve pricing or share for available manufacturers, but these effects are usually not durable.
Revenue exposure
| Revenue driver |
Impact on Cyklokapron |
| Generic substitution |
Negative for branded price and share |
| Surgical procedure volumes |
Positive for injectable demand |
| Trauma protocols |
Positive for institutional volume |
| Postpartum hemorrhage adoption |
Positive, particularly in public-health systems |
| Hospital contracting |
Negative for brand pricing |
| Manufacturing shortages |
Potentially positive for available inventory |
| Oral generic competition |
Limits value in outpatient indications |
Cyklokapron is unlikely to be a material driver of Pfizer’s consolidated financial performance. Its strategic value is more consistent with portfolio continuity and hospital presence than with high-margin growth.
How do generic launch scenarios affect Cyklokapron?
The most probable generic market scenarios are:
Base case: stable generic supply
Several suppliers maintain approval and production. Hospitals use generic tranexamic acid as the default product, with Cyklokapron retained in selected formularies or where brand continuity is preferred.
Downside case: increased price compression
Additional ANDA suppliers or aggressive contract bidding reduce injectable prices. Cyklokapron becomes a limited-use brand with low share and minimal pricing power.
Supply-constrained case: temporary brand recovery
A manufacturing disruption, inspection issue or shortage at one or more generic suppliers increases demand for Cyklokapron. Pfizer may regain short-term volume, but the effect depends on inventory and distribution capacity.
Growth case: protocol expansion
More hospitals adopt tranexamic acid in trauma, cardiac surgery, orthopedics and postpartum hemorrhage. This would expand total unit demand, but generic suppliers would capture much of the incremental volume.
Are there Paragraph IV challenges to Cyklokapron?
Paragraph IV litigation is not a significant current risk category for Cyklokapron because the relevant core patent protection has expired and generic injectable products are already established in the U.S. market.
A Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable or not infringed. For an old product with no meaningful blocking patent estate, new market entry generally does not require a high-value patent challenge against the brand.
The remaining regulatory disputes, if any, are more likely to involve:
- Bioequivalence or pharmaceutical equivalence.
- Sterility and manufacturing compliance.
- Labeling.
- Product quality.
- Drug shortage allocation.
- Contracting and procurement.
What patent litigation affects Cyklokapron?
No major active patent litigation is central to the current Cyklokapron commercial outlook. The product’s principal risk is competitive erosion, not litigation-driven loss of exclusivity.
Litigation and settlement assessment
| Issue |
Current commercial relevance |
| Core composition patent litigation |
Low |
| Formulation patent litigation |
Low |
| Method-of-use litigation |
Limited and indication-specific |
| Generic launch settlements |
Low strategic importance |
| Antitrust or contracting disputes |
Possible but not central to product value |
| Manufacturing litigation |
More relevant than patent disputes if supply fails |
No important branded-generic settlement is required to explain the current availability of generic tranexamic acid injection. The market has already transitioned to post-exclusivity competition.
What formulations and methods of use are protected?
The standard Cyklokapron injectable formulation has limited defensible differentiation. The commercial product is a conventional sterile solution of tranexamic acid for intravenous administration.
Potentially protectable areas in the broader tranexamic acid field include:
- Sustained-release oral dosage forms.
- Topical delivery systems.
- Nasal or local formulations.
- Combination products.
- New dosing regimens.
- Procedure-specific methods of use.
- Delivery systems intended to reduce systemic exposure.
These areas do not materially restore exclusivity to standard Cyklokapron injection unless a separate product receives independent patent and regulatory protection.
Is there biosimilar risk for Cyklokapron?
There is no biosimilar risk because Cyklokapron is a synthetic small-molecule drug, not a biologic. The relevant competitive category is generic substitution under the ANDA pathway.
This distinction matters commercially:
- Biosimilars require complex comparability programs.
- Tranexamic acid generics rely on established small-molecule approval standards.
- Manufacturing complexity is meaningful because the product is sterile, but it is not comparable to biologic manufacturing.
- Price competition is therefore more direct and usually more severe than in many biologic markets.
What manufacturing and intellectual-property barriers remain?
Manufacturing is the main practical barrier to entry. Injectable tranexamic acid requires validated sterile production, reliable active pharmaceutical ingredient supply, container-closure integrity, particulate control and compliance with FDA current good manufacturing practices.
Manufacturing risk factors
- Sterile fill-finish capacity.
- API sourcing and quality consistency.
- Inspection outcomes.
- Vial and ampule availability.
- Hospital demand forecasting.
- Cold-chain and distribution requirements where applicable.
- Regulatory remediation after manufacturing observations.
These barriers can reduce the number of active suppliers even when patents are expired. A market with multiple approved products can still experience shortages if only a small number of manufacturers maintain commercial-scale sterile capacity.
How does Cyklokapron compare with Lysteda?
Cyklokapron and Lysteda contain the same active ingredient but occupy different markets.
| Attribute |
Cyklokapron |
Lysteda |
| Dosage form |
Injectable solution |
Oral tablet |
| Primary setting |
Hospital and procedural care |
Outpatient use |
| Main indications |
Hemophilia-related dental procedures and institutional bleeding management |
Heavy menstrual bleeding |
| Competitive structure |
Generic injectable competition |
Generic oral competition |
| Pricing power |
Low |
Low to moderate before generic erosion |
| Manufacturing barrier |
Sterile injectable production |
Oral solid-dose production |
Lysteda had a more conventional branded outpatient commercial model, while Cyklokapron is tied to institutional purchasing. Neither product has a strong current patent-based moat.
What geographic markets matter most?
The commercial opportunity is global, but market economics differ sharply by region.
United States
The U.S. market is highly genericized. Hospital purchasing groups, formularies and supply reliability determine share. Brand retention is limited unless the product has contractual, clinical or supply advantages.
Europe
National health systems and centralized procurement place pressure on price. Tranexamic acid is widely used in surgery, obstetrics and gynecology, with generic products generally dominant.
Emerging markets
Public-health programs, trauma care expansion, maternal-health initiatives and lower-cost procurement support volume growth. Regulatory standards and distribution infrastructure can limit consistent availability.
Japan and other regulated markets
Local reimbursement, approval and procurement rules determine brand and generic penetration. The product’s long clinical history supports acceptance, but price controls constrain revenue.
How strong is the Cyklokapron commercial franchise?
Cyklokapron has high clinical durability but low exclusivity strength.
| Dimension |
Assessment |
| Clinical utility |
High |
| Patent protection |
Very low |
| Brand differentiation |
Low to moderate |
| Generic vulnerability |
High |
| Volume resilience |
High |
| Pricing power |
Low |
| Supply-chain sensitivity |
Moderate to high |
| Revenue growth potential |
Low |
| Regulatory risk |
Low for the established indication; moderate for manufacturing compliance |
The franchise can remain commercially relevant for many years because tranexamic acid is inexpensive, familiar and clinically useful. That durability should not be confused with branded growth potential.
Key Takeaways
- Cyklokapron is Pfizer’s branded injectable tranexamic acid product.
- The product is mature and has no meaningful current patent or regulatory exclusivity.
- Generic tranexamic acid injection is the primary competitive threat.
- Pfizer does not separately disclose Cyklokapron revenue.
- Market demand is supported by surgery, trauma, postpartum hemorrhage and other bleeding-related uses.
- Unit demand can grow while branded revenue remains flat or declines because generic suppliers capture incremental volume.
- There is no biosimilar risk; competition occurs through the small-molecule generic pathway.
- Manufacturing quality, sterile capacity and supply reliability are more important than intellectual property.
- The financial outlook is stable for the active ingredient market but limited for the Cyklokapron brand.
FAQs
Is Cyklokapron still under patent protection?
No meaningful core patent protection remains for the mature injectable tranexamic acid product in the United States. Commercial competition is primarily generic.
Is tranexamic acid a high-growth pharmaceutical market?
It is a volume-resilient market with selected growth opportunities in trauma, surgery and obstetrics. It is not generally a high-growth branded pharmaceutical market because of low prices and generic competition.
Can hospitals substitute generic tranexamic acid for Cyklokapron?
Hospitals commonly use approved generic tranexamic acid injection as a substitute, subject to formulary, procurement and product-specific requirements.
Does Pfizer report Cyklokapron sales separately?
Pfizer’s public financial reporting does not provide a standalone Cyklokapron revenue line. Sales are incorporated into broader reporting categories.
What is the largest commercial risk to Cyklokapron?
The largest risk is further generic price erosion and loss of hospital purchasing share. Short-term supply shortages can offset that pressure, but they do not create durable exclusivity.
References
-
Pfizer Inc. (2023). Cyklokapron (tranexamic acid) injection prescribing information. U.S. Food and Drug Administration labeling database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA and product-specific regulatory information for tranexamic acid injection. FDA.
-
CRASH-2 Collaborators. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage. The Lancet, 376(9734), 23-32.
-
WOMAN Trial Collaborators. (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum haemorrhage. The Lancet, 389(10084), 2105-2116.
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.
-
Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Pfizer.
